SBBP News and Press, Strongbridge Biopharma plc From 11/21/20

The shares of small-cap biopharma concern are finally seeing some momentum as they rally off oversold levels. The company posted better-than-expected Q3 results in late October and have some potential catalysts on the horizon in 2021. We revisit this $2.50 biopharma name and updat...

DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, tod...

Looking For Top Penny Stocks Today? Penny stocks have been some of the most interesting stocks to watch this week. Most importantly, small cap stocks, in general, have captivated traders more-so than large caps. One of the reasons has to do with a search for volatility after Monday&...

The following slide deck was published by Strongbridge Biopharma plc in conjunction with their 2020 Q3 earnings call. For further details see: Strongbridge Biopharma plc 2020 Q3 - Results - Earnings Call Presentation

Strongbridge Biopharma plc (SBBP) Q3 2020 Earnings Conference Call Oct 29, 2020, 04:30 PM ET Company Participants Lindsay Rocco - Elixir Health, Public Relations John Johnson - CEO Fred Cohen - Chief Medical Officer Rob Lutz - CFO Scott Wilhoit - Chief Commercial Officer Rich Kollender - COO ...

Gainers: [[TRUP]] +16%. [[EQ]] +15.8%. [[PLT]] +14.8%. [[MHK]] +12.3%. [[SBBP]] +10%.Losers: [[AXGT]] -41%. [[COLM]] -16.4%. [[TWTR]] -15.8%. [[UUU]] -12.5%. [[OPK]] -8.3%. For further details see: TWTR, OPK, MHK and TRUP among after-hours movers

Strongbridge Biopharma (SBBP): Q3 Non-GAAP EPS of -$0.12 beats by $0.01; GAAP EPS of -$0.06 beats by $0.20.Revenue of $8.1M (+42.6% Y/Y) beats by $0.66M.Shares +3.17%.Press Release For further details see: Strongbridge Biopharma EPS beats by $0.01, beats on revenue

~ Company on Track to Submit New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021 Following the Reporting of Positive Top-line Data from the LOGICS Study in the Third Quarter of 2020 ~ ~...

A Phase 2 clinical trial, ACROBAT Edge, evaluating Crinetics Pharmaceuticals' (CRNX) lead candidate paltusotine (formerly CRN00808) for the treatment of acromegaly met the primary endpoint. Specifically, once-daily oral doses of paltusotine maintained insulin-like growth factor-1 (IGF-1) leve...

DUBLIN, Ireland and TREVOSE, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...